Organic letters

ACS applied materials & interfaces

Heliyon

Nanomaterials (Basel, Switzerland)

Dalton transactions (Cambridge, England : 2003)

Medicine

ACS omega

BMC Bioinformatics

colloids and surfaces b, biointerfaces

Biomacromolecules

european journal of endocrinology

international immunopharmacology

oncotarget

Frontiers in genetics

bioconjugate chemistry

journal of biomaterials science polymer edition

Pharmaceutics

Frontiers in oncology

European journal of radiology

the lancet psychiatry

ANZ journal of surgery

hepatology international

experimental cell research

molecular genetics & genomic medicine

Aging

Diagnostics (Basel, Switzerland)

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Cancer medicine

journal of experimental & clinical cancer research : cr

journal of paediatrics and child health

current cancer drug targets

The Journal of nutritional biochemistry

Zhongguo zhen jiu = Chinese acupuncture & moxibustion

euroasian journal of hepato-gastroenterology

Molecular oncology

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology

Cellular & molecular immunology

Journal of medical ultrasonics (2001)

hepatology research : the official journal of the japan society of hepatology

American journal of cancer research

clinical oncology (royal college of radiologists (great britain))

Clinical and experimental obstetrics & gynecology

[1] Semi-synthesis of β-keto-1,2,3-triazole derivatives from ethinylestradiol and evaluation of the cytotoxic activity.

[2] Acetylene and terminal alkyne complexes of copper(i) supported by fluorinated pyrazolates: syntheses, structures, and transformations.

[3] Mining featured biomarkers associated with vascular invasion in HCC by bioinformatics analysis with TCGA RNA sequencing data.

[4] In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties.

[5] Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation.

[6] Nonalcoholic Fatty Liver Disease in South Asia.

[7] Associations of mental distress with residency in conflict zones, ethnic minority status, and potentially modifiable social factors following conflict in Sri Lanka: a nationwide cross-sectional study.

[8] CircRNA Cdr1as functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression.

[9] The effect of progesterone and pregnenolone on diabetes status in Chinese rural population: a dose-response analysis from Henan Rural Cohort.

[10] Enantioselective Copper-Catalyzed Electrophilic Dearomative Azidation of β-Naphthols.

[11] Analysis of miRNA-mRNA regulatory network revealed key genes induced by aflatoxin B1 exposure in primary human hepatocytes.

[12] Occurrence of Mycotoxins in Extruded Commercial Cat Food.

[13] Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.

[14] In-flight emergencies: Medical kits are not good enough for kids.

[15] Achillin Increases Chemosensitivity to Paclitaxel, Overcoming Resistance and Enhancing Apoptosis in Human Hepatocellular Carcinoma Cell Line Resistant to Paclitaxel (Hep3B/PTX).

[16] Ultrafast Synthesizing Bismuth Mesoporous Nanolitchi Radiosensitizer Loading High Dose DOX for CT Guided Enhanced Chemoradiotherapy.

[17] Dual roles of glutathione S-transferase mu 1 in the development and metastasis of hepatocellular carcinoma.

[18] Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics.

[19] Conjugation of Phthalocyanine Photosensitizer with Poly(amidoamine) Dendrimer: Improved Solubility, Disaggregation and Photoactivity Against HepG2 Cells.

[20] Population-level utilization of anatomic resection in early hepatocellular carcinoma (≤5 cm): post-operative, middle- and long-term outcomes.

[21] A pipeline to create predictive functional networks: application to the tumor progression of hepatocellular carcinoma.

[22] Metabolism-associated molecular classification of hepatocellular carcinoma.

[23] A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma.

[24] Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma.

[25] Galactose-based Thermosensitive Nanogels for Targeted Drug Delivery of Iodoazomycin Arabinofuranoside (IAZA) for Theranostic Management of Hypoxic Hepatocellular Carcinoma.

[26] Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.

[27] Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.

[28] Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

[29] TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma and .

[30] Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

[31] Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data.

[32] Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.

[33] Identification of abnormally expressed genes and their roles in invasion and migration of hepatocellular carcinoma.

[34] Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study.

[35] PLinaS-g-PEG coated magnetic nanoparticles as a contrast agent for hepatocellular carcinoma diagnosis.

[36] Water-Soluble Pristine C60 Fullerene Inhibits Liver Alterations Associated with Hepatocellular Carcinoma in Rat

[37] analysis of risk factors for recurrence and metastasis in patients with hepatocellular carcinoma after liver transplantation

[38] menahydroquinone-4 prodrug: a promising candidate anti-hepatocellular carcinoma agent

[39] surgical resection for hepatocellular carcinoma in pregnancy: a case report

[40] the silence of muc2 mrna induced by promoter hypermethylation associated with hbv in hepatocellular carcinoma

[41] bioinformatics analysis of the gene expression profile of hepatocellular carcinoma: preliminary results

[42] tec expresses highly in hepatocellular carcinoma and is involved in drug resistance

[43] pre/post-treatment dynamic of inflammatory markers has prognostic value in patients with small hepatocellular carcinoma managed by stereotactic body radiation therapy

[44] clinical and epidemiological aspects of hepatocellular carcinoma in brazil

[45] aberrant p16ink4a methylation: relation to viral related chronic liver disease and hepatocellular carcinoma

[46] multiplexed proteomic approach for identification of serum biomarkers in hepatocellular carcinoma patients with normal afp

[47] first- and second-line targeted systemic therapy in hepatocellular carcinoma—an update on patient selection and response evaluation

[48] lncrna-uc002mbe.2 interacting with hnrnpa2b1 mediates akt deactivation and p21 up-regulation induced by trichostatin in liver cancer cells

[49] paraneoplastic dermatomyositis in hepatocellular carcinoma with colonic perforation: a case report

[50] alcoholic liver disease: role of cytokines

[51] oxidative phosphorylation activation is an important characteristic of dox resistance in hepatocellular carcinoma cells

[52] different sex-based responses of gut microbiota during the development of hepatocellular carcinoma in liver-specific tsc1-knockout mice

[53] a concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016

[54] metastatic hepatocellular carcinoma in the maxilla and mandible, an extremely rare presentation

[55] recombinant newcastle disease virus (ndv/anh-il-2) expressing human il-2 as a potential candidate for suppresses growth of hepatoma therapy

[56] c-myc—making liver sick: role of c-myc in hepatic cell function, homeostasis and disease

[57] prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation

[58] mexican consensus on the diagnosis and management of hepatocellular carcinoma

[59] an overview of biomarkers and molecular signatures in hcc

[60] micrornas in the evaluation and potential treatment of liver diseases

[61] delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma

[62] hepatocellular carcinoma in brazil: report of a national survey (florianópolis, sc, 1995)

[63] differentiating hepatocellular carcinoma from hepatitis c using metabolite profiling

[64] prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma

[65] transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival

[66] upregulated expression of a unique gene by hepatitis b x antigen promotes hepatocellular growth and tumorigenesis

[67] prognosis of hepatocellular carcinoma after liver transplantation: comparative analysis with partial hepatectomy

[68] mycotoxin: its impact on gut health and microbiota

[69] hepatocellular carcinoma: past and future of molecular target therapy

[70] hip joint and femur metastases as the first symptom of hepatocellular carcinoma detected by bone scintigraphy

[71] radiofrequency ablation for hepatocellular carcinoma - analysis of the clinical outcome

[72] involvement of 14-3-3 proteins in regulating tumor progression of hepatocellular carcinoma

[73] Sorting and biological characteristics analysis for side population cells in human primary hepatocellular carcinoma.

[74] Evaluation of ten years of intrauterine insemination results at a tertiary center.

[75] Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome.

[76] Re: Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation

[77] Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review.

[78] Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma.

[79] Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation.

[80] Single-cell sequencing combined with bulk RNA seq reveals the roles of natural killer cell in prognosis and immunotherapy of hepatocellular carcinoma.

[81] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[82] Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

[83] Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

[84] Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

[85] Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

[86] Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

[87] Intermediate stage hepatocellular carcinoma: a summary review

[88] Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

[89] Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

[90] Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

[91] Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

[92] Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

[93] Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

[94] Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

[95] Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

[96] Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

[97] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[98] Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

[99] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[100] Editorial: charting the future of hepatocellular carcinoma publications

[101] Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt